Drug intelligence / Profile preview

GCAN-101

Development stage: Discontinued
Lead developer: GammaCan
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

GCAN-101 is an experimental, plasma-derived intravenous immunoglobulin (IVIG) formulation developed as an immunostimulant for the treatment of various cancers, most notably metastatic melanoma. Developed by Gammacan International, the drug consists of purified polyclonal antibodies harvested from healthy donors. The therapeutic rationale was based on the observation that certain naturally occurring antibodies in the human immune repertoire can recognize and neutralize tumor-promoting factors or directly stimulate an anti-tumor immune response. Clinical development reached Phase 2 trials for melanoma, but the program was discontinued in the late 2000s following financial difficulties and restructuring at Gammacan International.

Other names: VIG-C

Beyond the preview

Go deeper on GCAN-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GCAN-101.

Explore the full profile